Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, Lammerts van Bueren J, Chiu C, Doshi P, Pérez-Galán P.

Haematologica. 2019 Jul 11. pii: haematol.2018.211904. doi: 10.3324/haematol.2018.211904. [Epub ahead of print]

2.

Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors.

Daum S, Magnusson JP, Pes L, Garcia Fernandez J, Chercheja S, Medda F, Nollmann FI, Koester SD, Perez Galan P, Warnecke A, Abu Ajaj K, Kratz F.

Nucl Med Mol Imaging. 2019 Jun;53(3):189-198. doi: 10.1007/s13139-019-00587-w. Epub 2019 Feb 20.

PMID:
31231439
3.

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini DM, Laurent C, Morin R, Lagarde JM, Ysebaert L, Ligat L, Jean C, Savina A, Klein C, Céspedes AM, Perez-Galan P, Fournié JJ, Bezombes C.

Oncoimmunology. 2018 Dec 17;8(3):1554175. doi: 10.1080/2162402X.2018.1554175. eCollection 2019.

PMID:
30723586
4.

Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.

Pes L, Koester SD, Magnusson JP, Chercheja S, Medda F, Abu Ajaj K, Rognan D, Daum S, Nollmann FI, Garcia Fernandez J, Perez Galan P, Walter HK, Warnecke A, Kratz F.

J Control Release. 2019 Feb 28;296:81-92. doi: 10.1016/j.jconrel.2019.01.010. Epub 2019 Jan 11.

PMID:
30639692
5.

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.

Castella M, Boronat A, Martín-Ibáñez R, Rodríguez V, Suñé G, Caballero M, Marzal B, Pérez-Amill L, Martín-Antonio B, Castaño J, Bueno C, Balagué O, González-Navarro EA, Serra-Pages C, Engel P, Vilella R, Benitez-Ribas D, Ortiz-Maldonado V, Cid J, Tabera J, Canals JM, Lozano M, Baumann T, Vilarrodona A, Trias E, Campo E, Menendez P, Urbano-Ispizua Á, Yagüe J, Pérez-Galán P, Rives S, Delgado J, Juan M.

Mol Ther Methods Clin Dev. 2018 Dec 6;12:134-144. doi: 10.1016/j.omtm.2018.11.010. eCollection 2019 Mar 15.

6.

Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas.

Roisman A, Castellano G, Navarro A, Gonzalez-Farre B, Pérez-Galan P, Esteve-Codina A, Dabad M, Heath S, Gut M, Bosio M, Bellot P, Salembier P, Oliveras A, Slavutsky I, Magnano L, Horn H, Rosenwald A, Ott G, Aymerich M, López-Guillermo A, Jares P, Martín-Subero JI, Campo E, Hernández L.

Br J Haematol. 2019 Feb;184(3):373-383. doi: 10.1111/bjh.15656. Epub 2018 Nov 22.

PMID:
30565652
7.

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.

Lee-Vergés E, Hanna BS, Yazdanparast H, Rodríguez V, Rodríguez ML, Giró A, Vidal-Crespo A, Rosich L, Amador V, Aymerich M, Villamor N, Delgado J, Lichter P, Pérez-Galán P, López-Guerra M, Campo E, Seiffert M, Colomer D.

Int J Cancer. 2019 Jun 1;144(11):2762-2773. doi: 10.1002/ijc.32010. Epub 2019 Jan 16.

PMID:
30468254
8.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, Esteve-Arenys A, Clot G, Guerrero-Hernández M, Rodríguez V, Soldini D, Valera A, Moros A, Climent F, González-Barca E, Mercadal S, Arenillas L, Calvo X, Mate JL, Gutiérrez-García G, Casanova I, Mangues R, Sanjuan-Pla A, Bueno C, Menéndez P, Martínez A, Colomer D, Tejedor RE, Teixidó J, Campo E, López-Guillermo A, Borrell JI, Colomo L, Pérez-Galán P, Roué G.

Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.

9.

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.

Lozano E, Díaz T, Mena MP, Suñe G, Calvo X, Calderón M, Pérez-Amill L, Rodríguez V, Pérez-Galán P, Roué G, Cibeira MT, Rosiñol L, Isola I, Rodríguez-Lobato LG, Martin-Antonio B, Bladé J, Fernández de Larrea C.

J Immunol. 2018 Apr 15;200(8):2581-2591. doi: 10.4049/jimmunol.1701622. Epub 2018 Mar 12.

10.

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, Salaverria I, Campo E, Colomer D, Martinez A, Rymkiewicz G, Pérez-Galán P, Lopez-Guillermo A, Roué G.

Oncogene. 2018 Apr;37(14):1830-1844. doi: 10.1038/s41388-017-0111-1. Epub 2018 Jan 22.

PMID:
29353886
11.

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Body S, Esteve-Arenys A, Miloudi H, Recasens-Zorzo C, Tchakarska G, Moros A, Bustany S, Vidal-Crespo A, Rodriguez V, Lavigne R, Com E, Casanova I, Mangues R, Weigert O, Sanjuan-Pla A, Menéndez P, Marcq B, Picquenot JM, Pérez-Galán P, Jardin F, Roué G, Sola B.

Sci Rep. 2017 Oct 24;7(1):13946. doi: 10.1038/s41598-017-14222-1.

12.

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Giné E, Navarro A, Beà S, Campo E, López-Guillermo A, Lopez-Guerra M, Roué G, Colomer D, Pérez-Galán P.

Haematologica. 2017 Nov;102(11):e447-e451. doi: 10.3324/haematol.2017.168930. Epub 2017 Aug 24. No abstract available.

13.

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.

Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, Roué G, de Larrea CF.

Haematologica. 2017 Oct;102(10):1776-1784. doi: 10.3324/haematol.2017.164632. Epub 2017 Jul 27.

14.

Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.

Solé C, Martínez D, Giné E, Gonzalez-Farre B, Pérez-Galán P, Roncador G, Campo E, Matutes E, López-Guillermo A, Roué G, Martínez A.

Leuk Lymphoma. 2018 Feb;59(2):482-485. doi: 10.1080/10428194.2017.1330470. Epub 2017 Jun 2. No abstract available.

PMID:
28573896
15.

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.

Balsas P, Esteve-Arenys A, Roldán J, Jiménez L, Rodríguez V, Valero JG, Chamorro-Jorganes A, de la Bellacasa RP, Teixidó J, Matas-Céspedes A, Moros A, Martínez A, Campo E, Sáez-Borderías A, Borrell JI, Pérez-Galán P, Colomer D, Roué G.

J Hematol Oncol. 2017 Mar 31;10(1):80. doi: 10.1186/s13045-017-0447-6.

16.

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P.

Clin Cancer Res. 2017 Mar 15;23(6):1493-1505. doi: 10.1158/1078-0432.CCR-15-2095. Epub 2016 Sep 16.

17.

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.

Montraveta A, Lee-Vergés E, Roldán J, Jiménez L, Cabezas S, Clot G, Pinyol M, Xargay-Torrent S, Rosich L, Arimany-Nardí C, Aymerich M, Villamor N, López-Guillermo A, Pérez-Galán P, Roué G, Pastor-Anglada M, Campo E, López-Guerra M, Colomer D.

Oncotarget. 2016 Feb 2;7(5):5507-20. doi: 10.18632/oncotarget.6685.

18.

4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.

Puig de la Bellacasa R, Roué G, Balsas P, Pérez-Galán P, Teixidó J, Colomer D, Borrell JI.

Eur J Med Chem. 2014 Oct 30;86:664-75. doi: 10.1016/j.ejmech.2014.09.018. Epub 2014 Sep 6.

PMID:
25222877
19.

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.

Oncotarget. 2014 Aug 30;5(16):6788-800.

20.

A cyclization-rearrangement cascade for the synthesis of structurally complex chiral gold(I)-aminocarbene complexes.

Kolundžić F, Murali A, Pérez-Galán P, Bauer JO, Strohmann C, Kumar K, Waldmann H.

Angew Chem Int Ed Engl. 2014 Jul 28;53(31):8122-6. doi: 10.1002/anie.201403651. Epub 2014 Jul 7.

PMID:
25044294
21.

Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).

Matas-Céspedes A, Rodriguez V, Kalko SG, Vidal-Crespo A, Rosich L, Casserras T, Balsas P, Villamor N, Giné E, Campo E, Roué G, López-Guillermo A, Colomer D, Pérez-Galán P.

Clin Cancer Res. 2014 Jul 1;20(13):3458-71. doi: 10.1158/1078-0432.CCR-14-0154. Epub 2014 May 5.

22.

The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.

López-Guerra M, Xargay-Torrent S, Rosich L, Montraveta A, Roldán J, Matas-Céspedes A, Villamor N, Aymerich M, López-Otín C, Pérez-Galán P, Roué G, Campo E, Colomer D.

Leukemia. 2015 Jan;29(1):96-106. doi: 10.1038/leu.2014.143. Epub 2014 Apr 30.

PMID:
24781018
23.

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.

Moros A, Rodríguez V, Saborit-Villarroya I, Montraveta A, Balsas P, Sandy P, Martínez A, Wiestner A, Normant E, Campo E, Pérez-Galán P, Colomer D, Roué G.

Leukemia. 2014 Oct;28(10):2049-59. doi: 10.1038/leu.2014.106. Epub 2014 Mar 18.

PMID:
24721791
24.

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.

Montraveta A, Xargay-Torrent S, López-Guerra M, Rosich L, Pérez-Galán P, Salaverria I, Beà S, Kalko SG, de Frias M, Campàs C, Roué G, Colomer D.

Oncotarget. 2014 Feb 15;5(3):726-39.

26.

The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.

Rosich L, Saborit-Villarroya I, López-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M, Villamor N, Campo E, Pérez-Galán P, Roué G, Colomer D.

Haematologica. 2013 Nov;98(11):1739-47. doi: 10.3324/haematol.2013.088849. Epub 2013 Jul 12.

27.

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.

Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, Buggy JJ, Aue G, Tisdale JF, Pérez-Galán P, Wiestner A.

Leukemia. 2013 Dec;27(12):2311-21. doi: 10.1038/leu.2013.131. Epub 2013 Apr 26.

28.

SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.

Vegliante MC, Palomero J, Pérez-Galán P, Roué G, Castellano G, Navarro A, Clot G, Moros A, Suárez-Cisneros H, Beà S, Hernández L, Enjuanes A, Jares P, Villamor N, Colomer D, Martín-Subero JI, Campo E, Amador V.

Blood. 2013 Mar 21;121(12):2175-85. doi: 10.1182/blood-2012-06-438937. Epub 2013 Jan 15.

29.

Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.

Xargay-Torrent S, López-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Pérez-Galán P, Roué G, Campo E, Colomer D.

Clin Cancer Res. 2013 Feb 1;19(3):586-97. doi: 10.1158/1078-0432.CCR-12-1935. Epub 2012 Dec 11.

30.

Targeting the ubiquitin proteasome system: beyond proteasome inhibition.

Xolalpa W, Perez-Galan P, Rodríguez MS, Roué G.

Curr Pharm Des. 2013;19(22):4053-93. Review.

PMID:
23181575
31.

The role of cyclobutenes in gold(I)-catalysed skeletal rearrangement of 1,6-enynes.

Escribano-Cuesta A, Pérez-Galán P, Herrero-Gómez E, Sekine M, Braga AA, Maseras F, Echavarren AM.

Org Biomol Chem. 2012 Aug 14;10(30):6105-11. doi: 10.1039/c2ob25419k. Epub 2012 May 31.

PMID:
22648404
32.

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.

Clin Cancer Res. 2012 Apr 1;18(7):1979-91. doi: 10.1158/1078-0432.CCR-11-2113. Epub 2012 Feb 20.

33.

Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.

López-Guerra M, Xargay-Torrent S, Pérez-Galán P, Saborit-Villarroya I, Rosich L, Villamor N, Aymerich M, Roué G, Campo E, Montserrat E, Colomer D.

Leukemia. 2012 Jun;26(6):1429-32. doi: 10.1038/leu.2011.364. Epub 2011 Dec 20. No abstract available.

PMID:
22182921
34.

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Le Gouill S, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E; European Mantle Cell Lymphoma Network.

Leuk Lymphoma. 2011 Dec;52(12):2226-36. doi: 10.3109/10428194.2011.600488. Epub 2011 Aug 18. Review.

PMID:
21851218
35.

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.

Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.

Clin Cancer Res. 2011 Aug 1;17(15):5101-12. doi: 10.1158/1078-0432.CCR-10-3367. Epub 2011 Jun 28.

36.

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.

Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D.

Blood. 2011 Jan 27;117(4):1270-9. doi: 10.1182/blood-2010-04-278853. Epub 2010 Nov 24.

37.

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.

Blood. 2011 Jan 13;117(2):542-52. doi: 10.1182/blood-2010-02-269514. Epub 2010 Oct 18.

38.

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.

Blood. 2011 Jan 13;117(2):563-74. doi: 10.1182/blood-2010-05-284984. Epub 2010 Oct 12.

39.

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Pérez-Galán P, Dreyling M, Wiestner A.

Blood. 2011 Jan 6;117(1):26-38. doi: 10.1182/blood-2010-04-189977. Epub 2010 Oct 12. Review.

40.

Carbocations or cyclopropyl gold carbenes in cyclizations of enynes.

Pérez-Galán P, Martin NJ, Campaña AG, Cárdenas DJ, Echavarren AM.

Chem Asian J. 2011 Feb 1;6(2):482-6. doi: 10.1002/asia.201000557. Epub 2010 Oct 8.

PMID:
20936667
41.

Metal-arene interactions in dialkylbiarylphosphane complexes of copper, silver, and gold.

Pérez-Galán P, Delpont N, Herrero-Gómez E, Maseras F, Echavarren AM.

Chemistry. 2010 May 10;16(18):5324-32. doi: 10.1002/chem.200903507. Erratum in: Chemistry. 2011 Nov 4;17(45):12537.

PMID:
20394085
42.

Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells.

López-Royuela N, Pérez-Galán P, Galán-Malo P, Yuste VJ, Anel A, Susín SA, Naval J, Marzo I.

Biochem Pharmacol. 2010 Jun 15;79(12):1746-58. doi: 10.1016/j.bcp.2010.02.010. Epub 2010 Feb 24.

PMID:
20188077
43.

p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.

López-Guerra M, Roué G, Pérez-Galán P, Alonso R, Villamor N, Montserrat E, Campo E, Colomer D.

Clin Cancer Res. 2009 Apr 15;15(8):2767-76. doi: 10.1158/1078-0432.CCR-08-2382. Epub 2009 Apr 7.

44.

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.

Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, Ron D, Chen W, Trenkle W, Wiestner A, Ye Y.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2200-5. doi: 10.1073/pnas.0807611106. Epub 2009 Jan 22.

45.

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.

Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D.

Clin Cancer Res. 2008 Nov 1;14(21):6907-15. doi: 10.1158/1078-0432.CCR-08-0388.

46.

Gold(I) complexes with hydrogen-bond supported heterocyclic carbenes as active catalysts in reactions of 1,6-enynes.

Bartolomé C, Ramiro Z, Pérez-Galán P, Bour C, Raducan M, Echavarren AM, Espinet P.

Inorg Chem. 2008 Dec 1;47(23):11391-7. doi: 10.1021/ic801446v.

PMID:
18947178
47.

Gold(I)-catalyzed intermolecular addition of carbon nucleophiles to 1,5- and 1,6-enynes.

Amijs CH, López-Carrillo V, Raducan M, Pérez-Galán P, Ferrer C, Echavarren AM.

J Org Chem. 2008 Oct 3;73(19):7721-30. doi: 10.1021/jo8014769. Epub 2008 Aug 30.

PMID:
18759485
48.

BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.

Pérez-Galán P, Roué G, López-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D.

Leukemia. 2008 Sep;22(9):1712-20. doi: 10.1038/leu.2008.175. Epub 2008 Jul 3.

PMID:
18596739
49.

Gold(I)-catalyzed intramolecular [4+2] cycloadditions of arylalkynes or 1,3-enynes with alkenes: scope and mechanism.

Nieto-Oberhuber C, Pérez-Galan P, Herrero-Gómez E, Lauterbach T, Rodríguez C, López S, Bour C, Rosellón A, Cardenas DJ, Echavarren AM.

J Am Chem Soc. 2008 Jan 9;130(1):269-79. Epub 2007 Dec 13.

PMID:
18076170
50.

Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level.

Roué G, Pérez-Galán P, López-Guerra M, Villamor N, Campo E, Colomer D.

J Immunol. 2007 Feb 1;178(3):1923-30.

Supplemental Content

Loading ...
Support Center